ArticleDiabetes, obesity & metabolism2026
Use of sodium-glucose cotransporter-2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of sodium-glucose cotransporter-2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsClinical guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real-world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada. MATERIALS AND
methodsWe conducted a drug utilisation study on all individuals aged ≥75 years with T2DM in British Columbia between January 1, 2016, and December 31, 2023, using administrative healthcare databases. We examined prevalence, incidence, characteristics of incident users, and discontinuation.
resultsThe prevalence of SGLT2i use increased gradually from 2.0% in the first half of 2016 to 14% in the second half of 2022, then more sharply to 21% in the second half of 2023, with comparable prevalence in individuals with and without cardiorenal disease (20% vs. 22% in 2023). SGLT2i initiation increased from 1.3 to 2.8 per 1000 individuals between 2016 and 2022, spiked to 5.4 per 1000 individuals in January 2023, and then stabilised. Of the 14 320 SGLT2i initiators between 2021 and 2023, 62% had cardiorenal disease, most used other glucose-lowering drugs concomitantly (particularly metformin [68%], sulfonylureas [39%], and insulins [19%]), and 62% were started on treatment by a general practitioner. Additionally, 17% discontinued treatment within a year.
conclusionsSGLT2i use among older adults with T2DM in British Columbia increased steadily from 2016 to 2022, followed by a spike in 2023, aligned with the expansion in publicly funded drug coverage. By the end of 2023, around one in five used SGLT2is, regardless of cardiorenal disease status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.